As genomics-focused pharmacology begins to play a greater role in cancer treatment, next-generation sequencing (NGS) has emerged as a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors. With targeted therapies becoming the new standard of care in oncology, NGS-driven companion diagnostics are widely seen as driving the selection of treatments to optimize patient outcomes in the future.
Compared to traditional methods, NGS offers advantages in accuracy, sensitivity, and speed that has the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, it eliminates the need to order multiple tests to identify the causative mutation.
This multigene approach decreases the time to answer, providing a more economical solution and reducing the risk of exhausting precious clinical samples. In addition, NGS can provide high sensitivity, enabling the detection of mutations present at as little as 5% of the DNA isolated from a tumor sample.
NGS has the potential to change the future of oncology and advance the promise of personalized medicine. We invite you to learn more by examining the resources collected here.
In January, Illumina received exciting news about the opportunity to expedite FDA approval for breakthrough technologies. Read the announcement to see what it means for the TruSight Oncology assay.Read Article
This next-generation sequencing approach consolidates hundreds of cancer-related biomarkers, including different variant types, into a single assay. Explore the benefits and find out how it compares to other common cancer NGS methods.Learn More About CGP
AJ Patel had six months to live. Eight years later, he tells us how biomarker testing changed everything.Read Article
Key opinion leaders discuss the ongoing challenges and potential of NGS in oncology testing.Read Interview
San Diego-based molecular diagnostics company PetDx wants to help your four-legged friendRead Article
NGS can help clinical cancer researchers estimate TMB, identify neoantigens, and study innovative therapies to boost the immune response.Learn More
NGS offers the sensitivity and specificity that clinical researchers need to detect low levels of circulating tumor DNA (ctDNA) in the bloodstream.Learn More
Explore the benefits of NGS and microarrays for analyzing altered methylation patterns and other epigenetic changes in cancer.Learn More